CymaBay Therapeutics Inc (NASDAQ:CBAY) shares saw unusually-strong trading volume on Wednesday . Approximately 4,816,100 shares changed hands during trading, an increase of 295% from the previous session’s volume of 1,220,599 shares.The stock last traded at $1.56 and had previously closed at $1.55.
A number of research analysts recently issued reports on CBAY shares. Stifel Nicolaus lowered CymaBay Therapeutics from a “buy” rating to a “hold” rating and set a $4.00 target price on the stock. in a report on Monday, November 25th. Svb Leerink reaffirmed a “market perform” rating on shares of CymaBay Therapeutics in a report on Thursday, January 2nd. Leerink Swann lowered CymaBay Therapeutics to a “hold” rating and set a $2.50 target price on the stock. in a report on Tuesday, November 26th. Roth Capital lowered CymaBay Therapeutics from a “buy” rating to a “neutral” rating and lowered their target price for the stock from $22.00 to $2.00 in a report on Tuesday, November 26th. Finally, Zacks Investment Research raised CymaBay Therapeutics from a “hold” rating to a “buy” rating and set a $2.25 target price on the stock in a report on Tuesday, January 7th. One equities research analyst has rated the stock with a sell rating, ten have issued a hold rating and five have given a buy rating to the company. The stock has a consensus rating of “Hold” and an average price target of $6.56.
The company has a debt-to-equity ratio of 0.01, a quick ratio of 13.12 and a current ratio of 13.12. The company has a 50 day simple moving average of $1.81 and a two-hundred day simple moving average of $3.96. The company has a market cap of $107.17 million, a PE ratio of -1.15 and a beta of 1.20.
About CymaBay Therapeutics (NASDAQ:CBAY)
CymaBay Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on developing and providing therapies to treat liver and other chronic diseases. Its lead product candidate is seladelpar, a selective agonist of peroxisome proliferator-activated receptor delta, which has completed Phase II clinical study for the treatment of primary biliary cholangitis, as well as patients with nonalcoholic steatohepatitis.
Featured Article: How accurate is the Rule of 72?
Receive News & Ratings for CymaBay Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CymaBay Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.